Meet Dr. Banapour

            Dr. Pooya Banapour is a distinguished board-certified and fellowship-trained urologic oncologist, currently serving as a full-time practicing surgeon with a high-volume practice. His expertise spans urologic oncology, general urology, reconstructive urology, and female urology, making him a sought-after consultant for companies, hedge funds, private equity firms, and investment companies.

Dr. Banapour has extensive experience in treating a range of urologic conditions, including benign prostatic hyperplasia (BPH), overactive bladder, kidney stones, urinary incontinence, and various urologic malignancies such as prostate, kidney, bladder, and testicular cancer. His subspecialty training in oncology and robotics allows him to proficiently perform open, laparoscopic, and robotic surgeries using the latest minimally-invasive surgical technologies and advanced therapeutics.

In addition to his clinical practice, Dr. Banapour has collaborated with multiple surgical programs across diverse healthcare systems, providing him with valuable insights into various organizational structures and operational efficiencies. His research and literature have been published in numerous peer-reviewed journals and medical texts, underscoring his commitment to advancing the field of urology.

Dr. Banapour's consulting experience with industry leaders equips him with the knowledge to offer clients cutting-edge, evidence-based guidance in urology, oncology, surgery, and medicine. His unique combination of clinical expertise, innovative approach, and comprehensive industry experience positions him as a premier consultant for stakeholders seeking informed, strategic advice in the healthcare sector.

  • Society of Laparoscopic Surgeons Outstanding MIS Resident Award, 2018

    International Volunteers in Urology Resident Scholar, 2017 (Ajmer, India)

    Los Angeles Urologic Society Outstanding Resident Award, 2017

    International Volunteers in Urology Resident Scholarship recipient, 2017

    Kaiser Permanente Research Day finalist, 2016, 2017

    Top percentile in Urology In-service exam, 2016

    Western Section AUA Resident Bowl Regional Champion, 2016

    Western Section AUA Resident Scholarship recipient, 2016

    UCSD Regents Scholarship recipient, 2009-2013

    Latin Honors, summa cum laude, 2009

    Departmental Honors, Physiological Science, 2009

    Department of Physiological Science Outstanding Student Award, 2009

    UCLA Honors Program, 2005-2009

    Dean’s List, 2005-2009

    Governor’s Scholarship recipient, 2005-2008

  • Odeluga N, Banapour P, Choong K, et al. Safety and Feasibility of Robotic-Assisted Partial Nephrectomy and Partial Hepatectomy for Soft Tissue Sarcoma. Adv in Lap. 2022 May 27; 138-142.

    Banapour P, et al. Readmission and Complications after Robotic Surgery – Experience of 10,000 Operations at a Comprehensive Cancer Center. J Robot Surg. 2020 Apr 10.

    Banapour P, Elliott P, Jabaji R, Parekh A, Pathak A, Merchant M, Tamaddon K. Safety and feasibility of outpatient robot-assisted radical prostatectomy. J Robot Surg. 2019 Apr 13;2:261-5.

    Banapour P, Schumacher A, Lin J, Finley D. Radical Prostatectomy and Pelvic Lymph Node Dissection in Kaiser Permanente Southern California: a 15 year Experience. The Perm Journ. 2019 Dec 23:17-233.

    Jabaji R, Li V, Banapour P, Huang GO, Finley DS. Robotic partial cystectomy for venous malformation of the bladder. Urol Case Rep. 2018 Jul 6:20:65-66.

    Asanad K, Banapour P, Jabaji R, Chang A. Scrotal flap reconstruction for treatment of erectile dysfunction following penile enhancement with liquid silicone. Urol Case Rep. 2018 Jul 11;20:75-77.

    Banapour P, Jabaji R, Asanad K, Chien G, Bakhta Y. Paraneoplastic renal cell carcinoma in the setting of preeclampsia and placental abruption. Urol Case Rep. 2018 May 25;19:57-59.

    Banapour P, Abdelsayed GA, Bider Z, Elliott P, Kilday P, Chien GW. Nephrometry Score Matched Robotic vs. Laparoscopic vs. Open Partial Nephrectomy. J Robot Surg. 2018 Dec 12;4:679-85.

    Banapour P, Asanad K, Chan R, Tran V. Recurrent Papillary Renal Cell Carcinoma with Concomitant Ipsilateral Upper Urinary Tract Urothelial Carcinoma and Metachronous Urothelial Carcinoma of the Bladder. Urol Case Rep. 2018 Jan 12;17:59-61.

    Asanad K, Banapour P, Metzdorf M. Use of Diagnostic Laparoscopy for Identification of Bilateral Noncommunicating Hydroceles in an Infant with Right-Sided Abdominoscrotal Mass and Left-Sided Scrotal Mass. Case Rep Urol. 2017.

    Banapour P, Tenggardjaja C, Reyblat P. Anastomotic Urethroplasty for an Obstructing Calculus Within a Bulbar Urethral Diverticulum and Urethral Stricture. Urol Case Rep. 2016 Dec 8.

    Mitsinikos E, Abdelsayed GA, Bider Z, Kilday PS, Elliott PA, Banapour P, Chien GW. Does the Level of Assistant Experience Impact Operative Outcomes for Robot-Assisted Partial Nephrectomy? J Endourol. 2017 Dec 7.

    Banapour P, Sydorak RM, Shaul D. Surgical approach to intussusception in older children: influence of lead points. J Pediatr Surg. 2015 Oct 18.

    Mirheydar HS, Banapour P, Massoudi R, Palazzi KL, Jabaji R, Reid EG, Millard FE, Kane CJ, Sur RL. What is the incidence of kidney stones after chemotherapy in patients with lymphoproliferative or myeloproliferative disorders? Int Braz J Urol. 2014 Nov 4.

    Liss MA, Taylor SA, Banapour P, et al. Fluoroquinolone resistant rectal colonization predicts risk of infectious complications after transrectal prostate biopsy. J Urol 2017 Jun 10.

    Banapour P, Patel N, Kane CJ, Cohen SA, Parsons JK. Robotic-assisted simple prostatectomy: a systematic review and report of a single institution case series. Prostate Cancer Prostatic Dis. 2013 Dec 10.

  • Meng X, Banapour P, et al. CAPTAIN: A Randomized Controlled Trial of MRI-Guided Transurethral Ablation of the Prostate versus Radical Prostatectomy. Focal 2024, San Diego, CA. 

    Banapour P. Robotic assisted radical adrenalectomy for metastatic lung cancer: elucidation of surgical technique. WSAUA 2020.

    Banapour P. Reduction of benign ureteroenteric anastomotic stricture rate in extracorporeal urinary diversion using real-time indocyanine green angiography with fluorescence. WSAUA 2020.

    Banapour P. Readmission and complications after robotic surgery – experience of 10,000 operations at a comprehensive cancer center. WSAUA 2020.

    Banapour P, Cantrell A. Novel uses of ICG and Novadaq pinpoint system in reconstructive urology. WSAUA 2019, Monterey, CA.

    Banapour P, Shen J. Robotic-assisted radical nephroureterectomy for upper urinary tract malignancy in the elderly. WSAUA 2019, Monterey, CA.

    Banapour P, et al. Radical Prostatectomy and Pelvic Lymph Node Dissection in Kaiser Permanente Southern California: 15 year experience. WSAUA 2018, Maui, HI. 

    Banapour P, et al. Safety and Feasibility of Outpatient Robot assisted Radical Prostatectomy. WSAUA 2018, Maui, HI.

    Banapour P. Predictive value of MRI for Lymph Node involvement in men with high risk prostate cancer undergoing prostatectomy with extended pelvic lymphadenectomy. WSAUA 2017, Vancouver BC. 

    Banapour P. Can 1.5T MRI prostate accurately predict extracapsular extension in high risk prostate cancer patients? Los Angeles Urologic Society 2017, Westwood, CA. 

    Banapour P. Features of high-risk prostate cancer associated with changes in Gleason score following prostatectomy. Kaiser Los Angeles Surgery Grand Rounds, 2017. 

    Banapour P. Tumor and MRI Features Predictive of Extracapsular Extension in High risk prostate Cancer. AUA 2017, Boston MA. 

    Banapour P. Use of intravenous fluorescein dye for intraoperative identification of ureteral orifices: a single center experience. WSAUA 2016, Kaua’I, HI. 

    Banapour P. Radical nephrectomy for renal artery aneurysm (video presentation). WSAUA 2016, Kaua’I, HI. 

    Banapour P. Nephrometry Score Matched Robotic vs. Laparoscopic vs. Open Partial Nephrectomy. WSAUA 2015, Indian Wells CA. 

    Mirheydar, H, Banapour, P,Massoudi, R, Palazzi, K, Sisul, D, Sur, R. Prevalence of nephrolithiasis among patients on chemotherapy. WCE 2012. WSAUA 2012. 

  • Customized Ablation of the Prostate with the TULSA Procedure Against Radical Prostatectomy Treatment: A Randomized Controlled Trial for Localized Prostate Cancer, Principal Investigator.

    A Phase 3 Trial of BCG with or without Pembrolizumab (MK-3475) for HR NMIBC (KEYNOTE-676), Investigator.

    A Phase 3 Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib intravesical delivery system vs. single agent intravesical chemotherapy in participants with Intermediate Risk Non Muscle Invasiive Bladder Cancer (IR-NMIBC) and susceptible FGF-R alterations MOONRISE-1.

    A Multicenter, Prospective, Observational Study of patients being treated with Orgovyx (relugolix 120mg).

    A Two Stage, Lead-in and Randomized, Phase 2, Open Label Study of Darolutamide vs Enzalutamide as monotherapy on testosterone levels change in men with hormone naive prostate cancer (ARAMON).